Latest Version of Imprivata OneSign Improves Scalability and Expands Market-Leading Support for Desktop Virtualization Platforms and Thin/Zero Clients
Lexington, Mass.—December 2, 2014—Imprivata® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, today introduced Imprivata OneSign® 5.0, the newest version of the company’s flagship authentication and access management solution.
This video highlights the benefits of electronic prescribing of controlled substances (EPCS) and provides an overview of the DEA regulatory requirements for EPCS.
Methodist Health System (Omaha, Neb.) leverages fingerprint biometric authentication from Imprivata to enable e-Prescribing of controlled substances to improve patient satisfaction, eliminate dual-prescribing workflows and address drug diversion.